MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination

Vázquez, Susana; Valdés, Odaysa; Pupo, Maritza; Delgado, Iselys; Álvarez, Mayling; Pelegrino, José Luis; Guzmán, María G.

doi:10.1016/s0166-0934(03)00128-9

Cited by 51 publications

(37 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,11,23 Protective immunity after YF vaccination. Twelve studies in 11 articles 6,10,[25][26][27][28][29][30][31][32][33] addressed the efficacy of YF vaccine in terms of immunogenicity (Table 3). Seroconversion rates were consistently 90% in 9 of 10 studies.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Journal of Tropical Medicine and Hygiene

196

172

View full text Add to dashboard Cite

Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Journal of Tropical Medicine and Hygiene

196

172

View full text Add to dashboard Cite

show abstract

“…Limitations of anti-DENV IgM tests include their inability to identify the infecting DENV type and potential antibody cross-reactivity with other fl aviviruses (11,12). However, cross-reactivity to related viruses did not appear to be a problem with these tests.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests

Hunsperger¹,

Yoksan²,

Buchy³

et al. 2009

Emerg. Infect. Dis.

Self Cite

193

158

View full text Add to dashboard Cite

show abstract

“…This test performance is comparable to those assays traditionally used for detection of arboviruses, such as neutralization test (N), hemagglutination inhibition (HI), immunofluorescence (IF), and complement fixation (CF) 10,19,21,26 .…”

Section: Standardization Of Immunoenzymatic Assay (Elisa)mentioning

confidence: 74%

Circulation of antibodies against yellow fever virus in a simian population in the area of Porto Primavera Hydroelectric Plant, São Paulo, Brazil

Lima

Romano-Lieber

Duarte

2010

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYYellow fever (YF) is an acute viral infectious disease transmitted by mosquitoes which occurs in two distinct epidemiological cycles: sylvatic and urban. In the sylvatic cycle, the virus is maintained by monkey's infection and transovarian transmission in vectors. Surveillance of non-human primates is required for the detection of viral circulation during epizootics, and for the identification of unaffected or transition areas. An ELISA (enzyme-linked immunosorbent assay) was standardized for estimation of the prevalence of IgG antibodies against yellow fever virus in monkey sera (Alouatta caraya) from the reservoir area of Porto Primavera Hydroelectric Plant, in the state of São Paulo, Brazil. A total of 570 monkey sera samples were tested and none was reactive to antibodies against yellow fever virus. The results corroborate the epidemiology of yellow fever in the area. Even though it is considered a transition area, there were no reports to date of epizootics or yellow fever outbreaks in humans. Also, entomological investigations did not detect the presence of vectors of this arbovirus infection. ELISA proved to be fast, sensitive, an adequate assay, and an instrument for active search in the epidemiological surveillance of yellow fever allowing the implementation of prevention actions, even before the occurrence of epizootics.

show abstract

MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination

Cited by 51 publications

References 11 publications

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests

Circulation of antibodies against yellow fever virus in a simian population in the area of Porto Primavera Hydroelectric Plant, São Paulo, Brazil

Contact Info

Product

Resources

About